Literature DB >> 25217643

Ras regulates SCF(β-TrCP) protein activity and specificity via its effector protein NORE1A.

M Lee Schmidt1, Howard Donninger2, Geoffrey J Clark3.   

Abstract

Ras is the most frequently activated oncogene found in human cancer, but its mechanisms of action remain only partially understood. Ras activates multiple signaling pathways to promote transformation. However, Ras can also exhibit a potent ability to induce growth arrest and death. NORE1A (RASSF5) is a direct Ras effector that acts as a tumor suppressor by promoting apoptosis and cell cycle arrest. Expression of NORE1A is frequently lost in human tumors, and its mechanism of action remains unclear. Here we show that NORE1A forms a direct, Ras-regulated complex with β-TrCP, the substrate recognition component of the SCF(β-TrCP) ubiquitin ligase complex. This interaction allows Ras to stimulate the ubiquitin ligase activity of SCF(β-TrCP) toward its target β-catenin, resulting in degradation of β-catenin by the 26 S proteasome. However, the action of Ras/NORE1A/β-TrCP is substrate-specific because IκB, another substrate of SCF(β-TrCP), is not sensitive to NORE1A-promoted degradation. We identify a completely new signaling mechanism for Ras that allows for the specific regulation of SCF(β-TrCP) targets. We show that the NORE1A levels in a cell may dictate the effects of Ras on the Wnt/β-catenin pathway. Moreover, because NORE1A expression is frequently impaired in tumors, we provide an explanation for the observation that β-TrCP can act as a tumor suppressor or an oncogene in different cell systems.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  E3 Ubiquitin Ligase; Oncogene; Ras Protein; Tumor Suppressor Gene; Wnt Signaling

Mesh:

Substances:

Year:  2014        PMID: 25217643      PMCID: PMC4223314          DOI: 10.1074/jbc.M114.594283

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex.

Authors:  B A Schulman; A C Carrano; P D Jeffrey; Z Bowen; E R Kinnucan; M S Finnin; S J Elledge; J W Harper; M Pagano; N P Pavletich
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

2.  Destruction of Claspin by SCFbetaTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress.

Authors:  Niels Mailand; Simon Bekker-Jensen; Jiri Bartek; Jiri Lukas
Journal:  Mol Cell       Date:  2006-08-04       Impact factor: 17.970

3.  SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response.

Authors:  Angelo Peschiaroli; N Valerio Dorrello; Daniele Guardavaccaro; Monica Venere; Thanos Halazonetis; Nicholas E Sherman; Michele Pagano
Journal:  Mol Cell       Date:  2006-08-04       Impact factor: 17.970

4.  Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery.

Authors:  Ivan Mamely; Marcel Atm van Vugt; Veronique A J Smits; Jennifer I Semple; Bennie Lemmens; Anastassis Perrakis; René H Medema; Raimundo Freire
Journal:  Curr Biol       Date:  2006-08-24       Impact factor: 10.834

Review 5.  beta-catenin signaling and cancer.

Authors:  P J Morin
Journal:  Bioessays       Date:  1999-12       Impact factor: 4.345

6.  Beta-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases.

Authors:  Yoshinori Kanemori; Katsuhiro Uto; Noriyuki Sagata
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-21       Impact factor: 11.205

7.  Dual degradation signals control Gli protein stability and tumor formation.

Authors:  Erik G Huntzicker; Ivette S Estay; Hanson Zhen; Ludmila A Lokteva; Peter K Jackson; Anthony E Oro
Journal:  Genes Dev       Date:  2006-01-18       Impact factor: 11.361

8.  Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis.

Authors:  Joanne W Jang; Robert B Boxer; Lewis A Chodosh
Journal:  Mol Cell Biol       Date:  2006-08-14       Impact factor: 4.272

Review 9.  Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?

Authors:  C W Reuter; M A Morgan; L Bergmann
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

10.  H-Ras activation promotes cytoplasmic accumulation and phosphoinositide 3-OH kinase association of beta-catenin in epidermal keratinocytes.

Authors:  J Espada; M Pérez-Moreno; V M Braga; P Rodriguez-Viciana; A Cano
Journal:  J Cell Biol       Date:  1999-09-06       Impact factor: 10.539

View more
  10 in total

Review 1.  Intrinsic protein disorder in oncogenic KRAS signaling.

Authors:  Ruth Nussinov; Hyunbum Jang; Chung-Jung Tsai; Tsung-Jen Liao; Shuai Li; David Fushman; Jian Zhang
Journal:  Cell Mol Life Sci       Date:  2017-06-08       Impact factor: 9.261

Review 2.  Tumor suppressor C-RASSF proteins.

Authors:  Hiroaki Iwasa; Shakhawoat Hossain; Yutaka Hata
Journal:  Cell Mol Life Sci       Date:  2018-01-20       Impact factor: 9.261

Review 3.  The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence.

Authors:  Thibaut Barnoud; M Lee Schmidt; Howard Donninger; Geoffrey J Clark
Journal:  Cancer Lett       Date:  2017-04-26       Impact factor: 8.679

Review 4.  Pumping the brakes on RAS - negative regulators and death effectors of RAS.

Authors:  Desmond R Harrell Stewart; Geoffrey J Clark
Journal:  J Cell Sci       Date:  2020-02-10       Impact factor: 5.285

Review 5.  Ras signaling through RASSF proteins.

Authors:  Howard Donninger; M Lee Schmidt; Jessica Mezzanotte; Thibaut Barnoud; Geoffrey J Clark
Journal:  Semin Cell Dev Biol       Date:  2016-06-08       Impact factor: 7.727

6.  Ras Regulates Rb via NORE1A.

Authors:  Thibaut Barnoud; Howard Donninger; Geoffrey J Clark
Journal:  J Biol Chem       Date:  2015-12-16       Impact factor: 5.157

7.  NORE1A Regulates MDM2 Via β-TrCP.

Authors:  M Lee Schmidt; Diego F Calvisi; Geoffrey J Clark
Journal:  Cancers (Basel)       Date:  2016-03-23       Impact factor: 6.639

8.  Proteomics Analysis Reveals Novel RASSF2 Interaction Partners.

Authors:  Thibaut Barnoud; Daniel W Wilkey; Michael L Merchant; Jennifer A Clark; Howard Donninger
Journal:  Cancers (Basel)       Date:  2016-03-16       Impact factor: 6.639

9.  2-thio-6-azauridine inhibits Vpu mediated BST-2 degradation.

Authors:  Quan Zhang; Zeyun Mi; Yuming Huang; Ling Ma; Jiwei Ding; Jing Wang; Yongxin Zhang; Yang Chen; Jinming Zhou; Fei Guo; Xiaoyu Li; Shan Cen
Journal:  Retrovirology       Date:  2016-03-02       Impact factor: 4.602

10.  A 2-Benzylmalonate Derivative as STAT3 Inhibitor Suppresses Tumor Growth in Hepatocellular Carcinoma by Upregulating β-TrCP E3 Ubiquitin Ligase.

Authors:  Ting Peng; Orawan Wonganan; Zhonghui Zhang; Jialing Yu; Ruiying Xi; Yu Cao; Apichart Suksamrarn; Guolin Zhang; Fei Wang
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.